Pharmaceutical composition for treating diabetes mellitus
A technology for compound tablets and metformin tablets, applied in the field of medicine, can solve the problems of complicated operation, high equipment requirements, affecting drug release, etc., and achieve the effects of reducing irritation, improving dissolution rate, and solving the problem of content uniformity.
Active Publication Date: 2014-01-08
DISHA PHARMA GRP
View PDF6 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Due to the extremely low dosage of repaglinide, it is difficult to control the content uniformity of repaglinide
At the same time, in order to increase the compliance of patients, the amount of excipients should be reduced as much as possible to control the size of the tablet, but metformin hydrochloride has poor compressibility and plasticity, which brings certain difficulties to reasonably control the weight of the compound tablet
[0005] In the actual production process, the mixing process generally adopts the equal-volume incremental method, but its operation is cumbersome, the production efficiency is low, and it is difficult to achieve satisfactory results; CN102218064B discloses the use of repaglinide and metformin to mix and sieve repeatedly, and this method is complicated to operate , affecting the content uniformity of repaglinide
CN101516347A records that repaglinide is spray-dried to obtain repaglinide granules, wet granulated to obtain metformin hydrochloride granules, and the two granules are mixed and then compressed into tablets; CN101843617B prepares double-layer sustained-release tablets, which requires high equipment. It is difficult to industrialize, and the preparation process of double-layer sustained-release tablets will lead to excessive tablet hardness, which will affect drug release
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0023] Example 1, prescription: repaglinide 1g, metformin hydrochloride 500g, microcrystalline cellulose 15g, sorbitol 45g, povidone K30 20g, meglumine 2.5g, crospovidone XL-10 18.6g, polyethylene glycol 6000 12g, magnesium stearate 6.20g, Opadry coating powder 18.6g. Prepare 1000 tablets according to the preparation method described in the technical scheme section.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Property | Measurement | Unit |
---|---|---|
hardness | aaaaa | aaaaa |
Login to View More
Abstract
The invention relates to the technical field of a pharmaceutical composition for treating diabetes mellitus, particularly relates to a compound composition of repaglinide and metformin, and belongs to the technical field of medicine. According to the technical scheme, the pharmaceutical composition is a composite tablet of the repaglinide and the metformin and is characterized in that the repaglinide is micronized into 3-10 microns; the micronized repaglinide compound is dissolved into an ethanol solution of opadry and cladded at the periphery of an uncoated metformin tablet. The pharmaceutical composition has the beneficial effects that the preparation method is simplified; the cost is reduced; the stability of the medicine is improved.
Description
[0001] Technical field: The present invention relates to a compound pharmaceutical composition for treating diabetes, in particular to a compound composition of repaglinide and metformin, which belongs to the field of medical technology. Background of the invention: [0002] Diabetes is a metabolic disease characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological action, or both. The long-term high blood sugar in diabetes will lead to chronic damage and dysfunction of various tissues in the human body, especially the eyes, kidneys, heart, blood vessels, and nerves. [0003] Because some patients take a certain class of hypoglycemic drugs alone to control blood sugar is not ideal, and some patients have to stop taking a single drug because of large doses and serious adverse reactions. In recent years, two or even three drugs have been used clinically The combination of hypoglycemic drugs is becoming more and more common. [...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/451A61K9/30A61K47/32A61P3/10A61K31/155
Inventor 李金凤连艳菊许蕾
Owner DISHA PHARMA GRP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com